Founded in 2007 as Wellspharm and reestablished in 2019 as Wellspharmtech, our company has led the non-reimbursable medication market with pioneering products such as glutathione and Cindella injections. Leveraging our extensive pharmaceutical expertise and technology, we developed the cosmeceutical brand Dermagen, establishing relationships with over 2,000 clinics and hospitals, and launched the B2C brand Rapporapy to reach a broader audience. With a commitment to becoming a global pharmaceutical leader, we now operate across various segments, including non-reimbursable and prescription medications, medical devices, and cosmeceutical cosmetics, achieving sales and exports to approximately 50 countries.